

FSN Ref: FSN2022-02

FSCA Ref: QA2022-02 FSCA

Date: 07: 04: 2022

Urgent Field Safety Notice
Device Commercial Name

Dear valued customer

Contact details of local representative	
Name	Thermo Fisher Diagnostics AG
Address	Sennweidstrasse 46, 6312 Steinhausen
Email address	████████████████████
Telephone number	██████████

FSN Ref: FSN2022-02

FSCA Ref: QA2022-02 FSCA

Urgent Field Safety Notice (FSN)

Device Commercial Name
Risk addressed by FSN

1. Information of affected device(s)	
1.1	Device Types(s) Phadia™ Instrument
1.2	Commercial name(s) Phadia 200
1.3	Unique Device Identifier(s) (UDI-DI) 07333066016900
1.4	Primary clinical purpose of device(s) Phadia 200 is a fully automated instrument including software to be used together with dedicated in vitro diagnostic tests. The instrument is designed to handle processing of samples, reagents and calculation of analytical results from the measurement values. Phadia 200 is intended to be used in clinical laboratories.
1.5	Device Model/Catalogue/ part number(s) 12-4300-00
1.6	Affected serial or lot number range All serial numbers

2. Reason for Field Safety Corrective Action (FSCA)	
2.1	<p>Description of the problem</p> <p>An issue in the Phadia 200 software can cause the pipette to be placed too high above the dilution plate. This may cause the sample and diluent not being mixed properly and/or splashing of sample into other dilution wells. This can cause results to be between 7-230 % of the true value and may cause false negative or false positive results.</p> <p>ImmunoCAP™ and EliA™ test results may be affected if the following dilutions and tube settings are used:</p> <ul style="list-style-type: none"> • 1:50 • 1:100 • 1:200 • Tube setting with a bottom thickness >5 mm <p>ImmunoCAP and EliA tests that includes sample dilution according to these criteria are listed in appendix 1.</p>
2.2	<p>Hazards giving rise to the FSCA</p> <p>The issue may give false test results which may lead to the necessity of medical or surgical intervention. No residual risk for false test results if action is taken.</p>
2.3	<p>Probability of problem arising</p> <p>The frequency of possibly affected EliA tests when using tube settings with a bottom thickness >5 mm was estimated to be:</p> <ul style="list-style-type: none"> • 6 % (7908 possibly affected tests / 131 370 total number of tests) <p>For ImmunoCAP Specific IgG, the frequency of possibly affected tests when using tube settings with a bottom thickness >5 mm was estimated to be:</p> <ul style="list-style-type: none"> • 7 % (358 possibly affected tests / 5000 total number of tests)
2.4	<p>Predicted risk to patient/ users</p> <p>The probability for serious injury due to falsely decreased or increased EliA or ImmunoCAP Specific IgG results is estimated to be remote</p>


FSN Ref: FSN2022-02

FSCA Ref: QA2022-02 FSCA

3. Type of Action to mitigate the risk	
3.1	<p>Action(s) to be taken by the user</p> <p> <input type="checkbox"/> Identify Device <input type="checkbox"/> Quarantine Device <input type="checkbox"/> Return Device <input type="checkbox"/> Destroy Device <input type="checkbox"/> On-site device modification/inspection <input type="checkbox"/> Follow patient management recommendations <input type="checkbox"/> Take note of amendment/reinforcement of instructions for use (IFU) <input checked="" type="checkbox"/> Other A member of our Technical Support staff will contact you to schedule a visit to correct your instrument's tube settings and to investigate and inform you of possibly affected test results. If any possibly affected test results are identified, please determine if retesting of the samples is needed according to your internal operating procedures. Sign and return Customer Reply form FSN2022-02. <input type="checkbox"/> None </p>
3.2	<p>Is customer reply required? Yes</p>
3.3	<p>Action(s) to be taken by the manufacturer</p> <p> <input type="checkbox"/> Product removal <input checked="" type="checkbox"/> On-site device modification/ inspection <input type="checkbox"/> Software upgrade <input type="checkbox"/> IFU or labeling change <input checked="" type="checkbox"/> Other Corrective and preventive actions (CAPA) have been initiated to prevent this from recurring. The tube settings must be checked and changed on the Phadia 200 instrument. A search for potentially incorrect test results should be performed. <input type="checkbox"/> None </p>

FSN Ref: FSN2022-02

FSCA Ref: QA2022-02 FSCA

4. General information	
4.1	FSN type New
4.2	Manufacturer information
	Company name Phadia AB
	Address Rapsgatan 7P, PO Box 6460 75137 Uppsala, Sweden
4.3	The Competent (Regulatory) Authority of your country has been informed about this communication to customers
4.4	List of attachments/ appendices: <ul style="list-style-type: none"> • List of tests that may be affected by QA2022-02 • Customer Reply Form FSN2022-02
4.5	Name: Ales Bacak
	Title: Dipl. Ing.
	Signature: 

Appendix 1 – Tests that may be affected by QA2022-02

ImmunoCAP Specific IgG	EliA ssDNA
EliA RNP70	EliA ASCA IgG
EliA CENP	EliA anti-TPO
EliA CCP	EliA anti-TG
EliA GBM	EliA M2
EliA Celikey IgG	EliA Scl-70s
EliA Gliadin IgG	EliA RF IgG
EliA Jo-1	EliA RNA Pol III
EliA La	EliA Parietal Cell
EliA U1RNP	EliA Intrinsic Factor
EliA Ro	EliA SymphonyS
EliA Ro60	EliA LKM-1
EliA Rib P	EliA Celikey IgA
EliA GliadinDP IgG	EliA Gliadin IgA
EliA PR3S	EliA GliadinDP IgA
EliA Ro52	EliA RF IgA
EliA MPOS	EliA CCP IgA
EliA PM-Scl	EliA ASCA IgA
EliA Anti-IgA	EliA b2 Glycoprotein 1 IgM
EliA Fibrillarlin	EliA RF IgM
EliA Mi-2	EliA Calprotectin 2
EliA SmDP	

